Fresenius Medical Care Rejoins DAX 40 Index

Fresenius Medical Care, a global leader in products and services for individuals with kidney disease, is making a big move back to the DAX 40 index, which represents the 40 largest companies on the Frankfurt Stock Exchange. As of December 27, 2024, Fresenius Medical Care will once again be part of this prestigious group.

This return to the DAX 40 is a testament to the hard work and dedication of Fresenius Medical Care’s employees, who have been focused on delivering top-notch care for patients and value for shareholders. Helen Giza, CEO and Chair of the Management Board, expressed her excitement about this milestone, highlighting the company’s commitment to performance and strategic execution.

Since March 2023, Fresenius Medical Care has been part of the Mid-Cap DAX (MDAX), which tracks the 50 largest companies below the DAX 40. Prior to this, the company was a member of the DAX from September 1999.

Fresenius Medical Care serves around 4.1 million patients worldwide who regularly undergo dialysis treatment. With a network of 3,732 dialysis clinics, the company provides care for approximately 308,000 patients globally. Additionally, Fresenius Medical Care is a leading provider of dialysis products such as machines and dialyzers.

While this is an exciting development for Fresenius Medical Care, it’s essential to note that forward-looking statements in this release are subject to various risks and uncertainties. Factors such as changes in business conditions, legal and regulatory changes, and impacts related to the COVID-19 pandemic could affect actual results. Fresenius Medical Care remains committed to keeping its stakeholders informed about any updates or changes.

In conclusion, Fresenius Medical Care’s return to the DAX 40 index marks a significant achievement for the company and reflects its ongoing commitment to excellence in healthcare innovation and patient care.